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Abstract
For over a decade there has been intense interest given to the role
of procalcitonin in the diagnosis and management of sepsis in
critically ill patients. Early opinions strongly supported the diag-
nostic role but data accumulating from numerous subsequent
studies are less supportive, even when used in very selective
settings. Although there remains sufficient reason to support the
use of procalcitonin in guiding antibiotic therapy or perhaps
providing prognostic information, it may be time to focus our efforts
on the early diagnosis of sepsis in the critically care setting on
alternative, more promising methods.
Procalcitonin (PCT) has a fascination for many critical care
physicians. There exists the desire for reliable biomarkers of
sepsis; however, physicians are divided in opinion as to the
usefulness of this particular candidate. The study by Brodska
and colleagues published in the previous issue of Critical
Care is small, yet illuminating, searching to advance the
debate by evaluation of the behaviour and diagnostic role of
PCT in patients undergoing allogenic haematopoietic stem
cell transplantation, and who receive antithymocyte globulin
as part of the conditioning regimen [1]. Lacking indices such
as a white cell count to assist in determining whether sepsis
has occurred, the authors undertook a prospective trial to
ascertain the diagnostic values of PCT and C-reactive protein
in this very specialised situation. Marked and rapid elevations
of both C-reactive protein and PCT blood levels followed
antithymocyte globulin administration and performed
inadequately as markers for subsequent sepsis. It is probable
that the PCT was released from nonendocrine parenchymal
tissues throughout the body [2].
The story of PCT as a diagnostic marker in sepsis is an
unfinished story. Multiple studies undertaken over the past
decade have resulted in conflicting results, and the
heterogeneity of studies pose major challenges in arriving at a
consensus. This heterogeneity is expressed at several levels;
including experimental animal models that may vary from
endotoxin infusion to caecal ligation and puncture, methods
by which the diagnosis of sepsis and the nonseptic state in
humans are made, incomparable control groups, location of
septic foci and organism type, analytical methods used for
serum PCT levels, and the uncertainty of blood sampling in
regard to onset of infection. Such study complexity led to the
question of whether meta-analysis and systematic review
would help. Even here, the heterogeneity, as described
above, limits the power of any meta-analysis. There is value,
however, in reviewing multiple studies in this manner in an
attempt to elucidate appropriate use of PCT in everyday
clinical settings, even if the results do not provide support for
its use as an unequivocal marker of sepsis [3].
It could be argued that the strongest data available defy a
clear and accurate diagnostic role for PCT, but there is good
evidence to support a role in guiding the duration of antibiotic
therapy in patients with confirmed sepsis. Perhaps further
studies using more recently developed PCT assays, which
are more sensitive, may change this situation [4]. It is also
possible that large trials currently underway will resolve much
of the debate but, once again, the matter of heterogeneity will
need to be closely examined [5]. The lack of diagnostic
efficacy PCT demonstrated in the very selective group of
patients by Brodska and colleagues does not resolve the
major question: does PCT accurately diagnose the presence
of infection? More provocatively, there is another question
that should be asked – whether the time, money, and effort
put into defining the role of PCT may be better spent on more
promising areas of biomarker research such as genomics.
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